Somaform's Neural Interface Stays in Review as Debate Sharpens

The safety review of Somaform Augmetics' newest neural-interface line remains open and contested, regulators confirmed today, tamping down industry hopes that a clearance was imminent even as augmentation adoption edges past 5% of the global population. The review, which has run through the year without conclusion, centers on long-term integration risks that clinicians say the data cannot yet settle. Founder Julian Morrow, an augmentation-rights advocate, urged patience with the process while defending the technology's promise; independent neurologists urged more of it. "We owe people the truth that we don't know yet," said Dr. Hana Voss, a rehabilitation specialist in Geneva who fits augmented patients and has asked for slower approvals. For the roughly one in twenty humans already carrying an implant, the stakes are personal, not abstract. The paper notes only what is on the record: the line is under review, neither shipping nor cleared, and the argument around it is getting louder.